Aug 4, 2022
Longevity sirtuin clinical trial teases promising results
Posted by Paul Battista in categories: biotech/medical, life extension
New York’s Gorbunova Aging Research Center team is encouraged by frailty results from SIRT6 activator trial.
SIRT6, the so-called “longevity sirtuin” has been making rather a name for itself.
SIRT6 is a protein with an important job. It is vital for both normal base excision repair and double-strand break repair of DNA damage – damage that can lead to genomic instability, which ultimately contributing to aging. These repairs decline with age but can be boosted with SIRT6 [1].
Continue reading “Longevity sirtuin clinical trial teases promising results” »